Law360, New York ( June 21, 2011, 5:42 PM EDT) -- "Pay-for-delay" agreements or "reverse payment settlements" are agreements in which a branded drug company pays its potential competitor to abandon a patent challenge and delay offering a generic version. According to the Federal Trade Commission, "the number of patent settlements that included both compensation to the generic and a restriction on entry increased 60 percent, from 19 in FY 2009 to 31 in FY 2010."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.